Related Experiment Video
Updated: Nov 28, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
COVID-19 IgG/IgM antibody testing in Los Angeles County, California
Khadije Ahmad1, Vahid Rezvanizadeh1, Suraj Dahal1
1Division of Cardiology, Department of Internal Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, 1124 W Carson Street, Torrance, CA, 90502, USA.
Abstract:
Evidence suggests that asymptomatic and mild SARS-CoV-2 infections comprise > 95% of all cases. Developing a test that indicates past infection and possible immunity against the virus is important. We administered 244 antibody tests to three groups of high-risk population. The test consisted of an IgG component and an IgM component. The overall IgM/IgG positivity for patients with none, mild, moderate, and severe symptoms were 21.1%, 21.8%, 14.2%, and 26.9%, respectively. Those with moderate or severe symptoms were no more or less likely to have positive antibody tests than those with no or mild symptoms.

